














Digital twins, digital phenotyping and digital biomarkers represent the cutting edge of personalized healthcare and next-generation drug development. These digital representations of our health state constructed from a vast array of data sources including genetic information, health records, and real-time biometric feedback, provide a more holistic view of a patient, down to their biological age. Through AI and simulation technology, these digital patient twins can predict health risks, test treatment viability, and offer personalized care strategies before actual human intervention. As we continue down this pixel parallel, we’ll need to address data ownership and control among other ethical implications. How do we leverage the best of technology to realize the potential of truly personalized care? The future may hold your digital alter ego!